Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Thrombocytopenia D013921 15 associated lipids
Thrombocythemia, Essential D013920 9 associated lipids
Thromboangiitis Obliterans D013919 4 associated lipids
Thrombasthenia D013915 4 associated lipids
Takayasu Arteritis D013625 3 associated lipids
Tachycardia, Supraventricular D013617 3 associated lipids
Tachycardia, Paroxysmal D013614 2 associated lipids
Tachycardia D013610 7 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Strongyle Infections, Equine D013319 1 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Zhao Y et al. [The effect of desloratadine on the TXB2 and leukotrienes levels in the nasal lavage fluid of allergic rhinitis animal model]. 2005 Lin Chuang Er Bi Yan Hou Ke Za Zhi pmid:16075993
Yoshino T et al. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor. 2005 Arzneimittelforschung pmid:16080279
Mancini F et al. Time since menopause does not affect plasma viscosity, plasma thromboxane levels and Doppler findings. 2005 Gynecol. Endocrinol. pmid:16019357
Mancini F et al. Effects of hormone replacement therapy on plasma viscosity and Doppler variations in postmenopausal non-smokers and heavy smokers. 2005 Gynecol. Endocrinol. pmid:16019365
Michibayashi T Platelet aggregation and vasoconstriction related to platelet cyclooxygenase and 12-lipoxygenase pathways. 2005 J. Atheroscler. Thromb. pmid:16020916
Svenstrup Poulsen T et al. A critical appraisal of the phenomenon of aspirin resistance. 2005 Cardiology pmid:16020925
Walsh DS et al. Characterization of circulating monocytes expressing HLA-DR or CD71 and related soluble factors for 2 weeks after severe, non-thermal injury. 2005 J. Surg. Res. pmid:16045935
Rodrigue ME et al. Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats. 2005 Can. J. Physiol. Pharmacol. pmid:16049546
Coppola A et al. Reduced in vivo oxidative stress following 5-methyltetrahydrofolate supplementation in patients with early-onset thrombosis and 677TT methylenetetrahydrofolate reductase genotype. 2005 Br. J. Haematol. pmid:16173969
Blume C et al. Different effect of cyclosporine A and mycophenolate mofetil on passive Heymann nephritis in the rat. 2005 Nephron Exp. Nephrol. pmid:15855806
Giraudel JM et al. Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and predicting selectivity of nonsteroidal anti-inflammatory drugs in cats. 2005 Am. J. Vet. Res. pmid:15900953
Song YM et al. Effects of scorpion venom bioactive polypolypeptides on platelet aggregation and thrombosis and plasma 6-keto-PG F1alpha and TXB2 in rabbits and rats. 2005 Toxicon pmid:15975616
Hsiao G et al. Protective mechanisms of inosine in platelet activation and cerebral ischemic damage. 2005 Arterioscler. Thromb. Vasc. Biol. pmid:15976325
Montuschi P et al. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. 2005 Thorax pmid:16192367
Barbara J et al. Prevention of latex sensitization in guinea pigs by a bacterial and viral filter used in anaesthesia. 2005 Br J Anaesth pmid:15980041
Hsiao G et al. alpha-Naphthoflavone, a potent antiplatelet flavonoid, is mediated through inhibition of phospholipase C activity and stimulation of cyclic GMP formation. 2005 J. Agric. Food Chem. pmid:15969494
Munsterhjelm E et al. Characterization of inhibition of platelet function by paracetamol and its interaction with diclofenac in vitro. 2005 Acta Anaesthesiol Scand pmid:15954969
Vangroenweghe F et al. Effect of carprofen treatment following experimentally induced Escherichia coli mastitis in primiparous cows. 2005 J. Dairy Sci. pmid:15956299
Wakamoto S et al. Effects of hemoglobin vesicles on resting and agonist-stimulated human platelets in vitro. 2005 Artif Cells Blood Substit Immobil Biotechnol pmid:15960075
Al Kadi H et al. A prospective, longitudinal study of the renin-angiotensin system, prostacyclin and thromboxane in the first trimester of normal human pregnancy: association with birthweight. 2005 Hum. Reprod. pmid:16006463
Beretta C et al. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. 2005 Pharmacol. Res. pmid:15939622
Visioli F et al. Virgin Olive Oil Study (VOLOS): vasoprotective potential of extra virgin olive oil in mildly dyslipidemic patients. 2005 Eur J Nutr pmid:15309433
Jin YR et al. Antiplatelet activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization. 2005 J. Pharmacol. Exp. Ther. pmid:15328379
Jin YR et al. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets. 2005 Basic Clin. Pharmacol. Toxicol. pmid:16128910
Corazzi T et al. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). 2005 J. Pharmacol. Exp. Ther. pmid:16144976
Haubelt H et al. Can platelet function tests predict the clinical efficacy of aspirin? 2005 Semin. Thromb. Hemost. pmid:16149017
Ueda T and Hashimoto T [Thromboxane A2 (TXA2), thromboxane B2 (TXB2)]. 2005 Nippon Rinsho pmid:16149442
Francois H et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. 2005 Cell Metab. pmid:16154102
Jermany J et al. Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects. 2005 J Clin Pharmacol pmid:16172182
Persico N et al. Transdermal HRT and Doppler findings in normotensive and hypertensive postmenopausal patients. 2005 Ultrasound Obstet Gynecol pmid:16184506
Perini JA et al. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. 2005 Clin. Pharmacol. Ther. pmid:16198655
Davì G et al. Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. 2005 Arterioscler. Thromb. Vasc. Biol. pmid:15472127
Maree AO et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. 2005 J. Am. Coll. Cardiol. pmid:16198840
Cao D et al. Chronic administration of ethyl docosahexaenoate decreases mortality and cerebral edema in ischemic gerbils. 2005 Life Sci. pmid:16214179
Léger CL et al. A thromboxane effect of a hydroxytyrosol-rich olive oil wastewater extract in patients with uncomplicated type I diabetes. 2005 Eur J Clin Nutr pmid:15798774
Stichtenoth DO et al. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. 2005 Kidney Int. pmid:16221219
Saloheimo P et al. Thromboxane and prostacyclin biosynthesis in patients with acute spontaneous intracerebral hemorrhage. 2005 Thromb. Res. pmid:15733969
Trebino CE et al. Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages. 2005 J. Biol. Chem. pmid:15722356
Fimognari FL et al. Nocturnal rise of urinary thromboxane B 2 in patients with coronary artery disease. 2005 Thromb. Haemost. pmid:15735822
Mayer AM et al. Differential modulation of microglia superoxide anion and thromboxane B2 generation by the marine manzamines. 2005 BMC Pharmacol. pmid:15762999
Kalaitzis C et al. Effects of renal denervation of the contralateral kidney on blood pressure and sodium and eicosanoid excretion in the chronic phase of two-kidney, one-clip renovascular hypertension in rats. 2005 Scand. J. Urol. Nephrol. pmid:15764265
García-Saura MF et al. Effects of chronic quercetin treatment in experimental renovascular hypertension. 2005 Mol. Cell. Biochem. pmid:15792364
Awad AS et al. Increased renal production of angiotensin II and thromboxane B2 in conscious diabetic rats. 2005 Am. J. Hypertens. pmid:15831366
De Candia E et al. Abnormal pH-sensing of platelet Na+/H+ exchanger in patients with cardiac syndrome X. 2005 Int. J. Cardiol. pmid:15837078
Capone ML et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. 2005 J. Am. Coll. Cardiol. pmid:15837265
Oliveira RL et al. Postmenopausal hormone replacement therapy increases plasmatic thromboxane beta 2. 2005 Int. J. Cardiol. pmid:15771927
Cryer B et al. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. 2005 Clin Ther pmid:15811481
Lappegård KT et al. Differential effect of heparin coating and complement inhibition on artificial surface-induced eicosanoid production. 2005 Ann. Thorac. Surg. pmid:15734405
Kong XY and Gong PL [Effect of phenolic alkaloids of Menispermum dauricum on thrombosis and platelet aggregation]. 2005 Yao Xue Xue Bao pmid:16408809
Gerasimovska-Kitanovska B et al. Decreased nitric oxide in women with essential hypertension in prehypertensive phase. 2005 Croat. Med. J. pmid:16342341